- Home
- ATXS vs TKNO Comparison
ATXS vs TKNO Comparison
Compare ATXS & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- TKNO
- Stock Information
- Founded
- ATXS 2008
- TKNO 1996
- Country
- ATXS United States
- TKNO United States
- Employees
- ATXS N/A
- TKNO N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- ATXS Health Care
- TKNO Health Care
- Exchange
- ATXS Nasdaq
- TKNO Nasdaq
- Market Cap
- ATXS 401.2M
- TKNO 430.2M
- IPO Year
- ATXS 2015
- TKNO 2021
- Fundamental
- Price
- ATXS $6.81
- TKNO $7.45
- Analyst Decision
- ATXS Strong Buy
- TKNO Buy
- Analyst Count
- ATXS 6
- TKNO 2
- Target Price
- ATXS $25.67
- TKNO $5.00
- AVG Volume (30 Days)
- ATXS 244.9K
- TKNO 266.7K
- Earning Date
- ATXS 03-03-2025
- TKNO 03-04-2025
- Dividend Yield
- ATXS N/A
- TKNO N/A
- EPS Growth
- ATXS N/A
- TKNO N/A
- EPS
- ATXS N/A
- TKNO N/A
- Revenue
- ATXS N/A
- TKNO $36,347,000.00
- Revenue This Year
- ATXS N/A
- TKNO $3.47
- Revenue Next Year
- ATXS N/A
- TKNO $12.07
- P/E Ratio
- ATXS N/A
- TKNO N/A
- Revenue Growth
- ATXS N/A
- TKNO N/A
- 52 Week Low
- ATXS $6.64
- TKNO $1.16
- 52 Week High
- ATXS $16.90
- TKNO $10.37
- Technical
- Relative Strength Index (RSI)
- ATXS 31.94
- TKNO 38.57
- Support Level
- ATXS $6.77
- TKNO $7.76
- Resistance Level
- ATXS $7.30
- TKNO $8.45
- Average True Range (ATR)
- ATXS 0.30
- TKNO 0.62
- MACD
- ATXS 0.02
- TKNO -0.19
- Stochastic Oscillator
- ATXS 14.66
- TKNO 0.00
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.